{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.0","upperLimit":"13.0","value":"9.1"},{"groupId":"OG001","lowerLimit":"2.9","upperLimit":"15.5","value":"7.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"Estimate the median overall survival. Overall survival is defined as the duration of time from date of study entry until date of death or date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"This cohort will enroll patients with mesothelioma, uveal melanoma, renal cell carcinoma (clear cell type), and cholangiocarcinoma.\n\nNiraparib: Patients will take 300 mg of niraparib orally once daily each day of a 28 day cycle.","id":"OG000","title":"Cohort A"},{"description":"This cohort will enroll patients whose tumors have a known DNA damage response mutation in any of the following genes: ARID1A, ATM, ATR, BACH1 (BRIP1), BAP1, BARD1, BLM, CHEK1, CHEK2, CDK2, CDK4, ERCC, FAM175A, FEN1, IDH1, IDH2, MRE11A, NBN (NBS1), PALB2, POLD1, PRKDC (DNA-PK) PTEN, RAD50, RAD51, RAD52, RAD54, RPA1, SLX4, WRN, or XRCC. This cohort is open to patients with any type of malignancy (except prostate).\n\nNiraparib: Patients will take 300 mg of niraparib orally once daily each day of a 28 day cycle.","id":"OG001","title":"Cohort B"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"10 months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}